24 SCHOOL ST., 2ND FLOOR, BOSTON, MA
Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
News, Material Contracts
CEO to Present at Biomarkers & Precision Medicine 2025
Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Q2
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Q3
FY 2023 amended
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
RW
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Submission Upload
Correspondence